Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

TAT 2022 will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach.

ESMO TAT 2022

ESMO Targeted Anticancer Therapies Congress 2022
07–08 March 2022 | Virtual Meeting

ESMO TAT 2022

ESMO Targeted Anticancer Therapies Congress 2022
07–08 March 2022 | Virtual Meeting
TAT 2022 will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach.
Using imaging of steroid receptor and PARP targets to improve endocrine therapy 3:04
Using imaging of steroid receptor and PARP targets to improve endocrine therapy
David Mankoff • 30 Mar 2022
Total-body PET: Applications and unmet needs 7:52
Total-body PET: Applications and unmet needs
David Mankoff • 30 Mar 2022
Potential of molecular imaging be used as a biomarker in cancer care 3:52
Potential of molecular imaging be used as a biomarker in cancer care
David Mankoff • 30 Mar 2022
Unmet needs for early onset colorectal cancer 2:28
Unmet needs for early onset colorectal cancer
Elisa Fontana • 25 Mar 2022
TRESR trial: Novel ATR inhibitor, RP-3500, for advanced solid tumors 3:10
TRESR trial: Novel ATR inhibitor, RP-3500, for advanced solid tumors
Elisa Fontana • 25 Mar 2022
Importance of collaboration between imaging specialists and oncologists 2:18
Importance of collaboration between imaging specialists and oncologists
David Mankoff • 30 Mar 2022
Combination of WEE1 inhibition and immunotherapy provides promising preclinical data for SCLC 2:11
Combination of WEE1 inhibition and immunotherapy provides promising preclinical data for SCLC
Triparna Sen • 21 Mar 2022
DNA damage repair pathways and WEE1 as possible therapeutic targets in SCLC 2:15
DNA damage repair pathways and WEE1 as possible therapeutic targets in SCLC
Triparna Sen • 21 Mar 2022
Current therapeutic landscape for small-cell lung cancer 2:56
Current therapeutic landscape for small-cell lung cancer
Triparna Sen • 21 Mar 2022
Pre-clinical data for novel EGFR inhibitor BDTX-1535 3:28
Pre-clinical data for novel EGFR inhibitor BDTX-1535
Matthew Lucas • 22 Mar 2022
Unmet needs in NSCLC that EGFR inhibitor BDTX-1535 aims to address 4:04
Unmet needs in NSCLC that EGFR inhibitor BDTX-1535 aims to address
Matthew Lucas • 22 Mar 2022
Unmet needs in glioblastoma that EGFR inhibitor BDTX-1535 aims to address 4:54
Unmet needs in glioblastoma that EGFR inhibitor BDTX-1535 aims to address
Matthew Lucas • 22 Mar 2022
BDTX-1535: A novel treatment for EGFR-mutated NSCLC and glioblastoma 3:14
BDTX-1535: A novel treatment for EGFR-mutated NSCLC and glioblastoma
Matthew Lucas • 22 Mar 2022
How the Mutation-Allostery-Pharmacology platform aims to help patients with rare oncogenic mutations 2:20
How the Mutation-Allostery-Pharmacology platform aims to help patients with rare oncogenic mutations
Matthew Lucas • 22 Mar 2022
The content of VJOncology is intended for healthcare professionals